REFERENCES
1. Zhu RX, Seto WK, Lai CL, Yuen MF. Epidemiology of hepatocellular carcinoma in the Asia-Pacific Region. Gut Liver 2016;10:332-9.
2. Yang JD, Roberts LR. Hepatocellular carcinoma: a global view. Nat Rev Gastroenterol Hepatol 2010;7:448-58.
3. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90.
4. Buonaguro L, Mauriello A, Cavalluzzo B, Petrizzo A, Tagliamonte M. Immunotherapy in hepatocellular carcinoma. Ann Hepatol 2019;18:291-7.
5. Brown ZJ, Greten TF, Heinrich B. Adjuvant treatment of hepatocellular carcinoma: prospect of immunotherapy. Hepatology 2019;70:1437-42.
6. Obeid JM, Kunk PR, Zaydfudim VM, Bullock TN, Slingluff CL, Jr., Rahma OE. Immunotherapy for hepatocellular carcinoma patients: is it ready for prime time? Cancer Immunol Immunother 2018;67:161-74.
7. El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 2017;389:2492-502.
8. Leonardi GC, Candido S, Cervello M, Nicolosi D, Raiti F, et al. The tumor microenvironment in hepatocellular carcinoma (review). Int J Oncol 2012;40:1733-47.
9. Zhang Q, He Y, Luo N, Patel SJ, Han Y, et al. Landscape and dynamics of single immune cells in hepatocellular carcinoma. Cell 2019;179:829-45.e20.
10. Chew V, Lai L, Pan L, Lim CJ, Li J, et al. Delineation of an immunosuppressive gradient in hepatocellular carcinoma using high-dimensional proteomic and transcriptomic analyses. Proc Natl Acad Sci U S A 2017;114:E5900-9.
11. Zhang Z, Ma L, Goswami S, Ma J, Zheng B, et al. Landscape of infiltrating B cells and their clinical significance in human hepatocellular carcinoma. Oncoimmunology 2019;8:e1571388.
12. Ye L, Zhang Q, Cheng Y, Chen X, Wang G, et al. Tumor-derived exosomal HMGB1 fosters hepatocellular carcinoma immune evasion by promoting TIM-1(+) regulatory B cell expansion. J Immunother Cancer 2018;6:145.
13. Xue H, Lin F, Tan H, Zhu ZQ, Zhang ZY, et al. Overrepresentation of IL-10-expressing B cells suppresses cytotoxic CD4+ T cell activity in HBV-induced hepatocellular carcinoma. PLoS One 2016;11:e0154815.
14. Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and response rate to PD-1 inhibition. N Engl J Med 2017;377:2500-1.
15. Ou DL, Lin YY, Hsu CL, Lin YY, Chen CW, et al. Development of a PD-L1-expressing orthotopic liver cancer model: implications for immunotherapy for hepatocellular carcinoma. Liver Cancer 2019;8:155-71.
16. Zheng Y, Wang T, Tu X, Huang Y, Zhang H, et al. Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma. J Immunother Cancer 2019;7:193.
17. Kaseb AO, Vence L, Blando J, Yadav SS, Ikoma N, et al. Immunologic correlates of pathologic complete response to preoperative immunotherapy in hepatocellular carcinoma. Cancer Immunol Res 2019;7:1390-5.
18. Hong YK, Li Y, Pandit H, Li S, Pulliam Z, et al. Epigenetic modulation enhances immunotherapy for hepatocellular carcinoma. Cell Immunol 2019;336:66-74.
19. Zhan C, Ruohoniemi D, Shanbhogue KP, Wei J, Welling TH, et al. Safety of combined yttrium-90 radioembolization and immune checkpoint inhibitor immunotherapy for hepatocellular carcinoma. J Vasc Interv Radiol 2020;31:25-34.
20. Wesley JD, Whitmore J, Trager J, Sheikh N. An overview of sipuleucel-T: autologous cellular immunotherapy for prostate cancer. Hum Vaccin Immunother 2012;8:520-7.
21. Gao F, Zhu HK, Zhu YB, Shan QN, Ling Q, et al. Predictive value of tumor markers in patients with recurrent hepatocellular carcinoma in different vascular invasion pattern. Hepatobiliary Pancreat Dis Int 2016;15:371-7.
22. Shimizu Y, Suzuki T, Yoshikawa T, Endo I, Nakatsura T. Next-generation cancer immunotherapy targeting glypican-3. Front Oncol 2019;9:248.
23. Sang M, Wang L, Ding C, Zhou X, Wang B, et al. Melanoma-associated antigen genes - an update. Cancer Lett 2011;302:85-90.
24. Castelli C, Rivoltini L, Andreola G, Carrabba M, Renkvist N, et al. T-cell recognition of melanoma-associated antigens. J Cell Physiol 2000;182:323-31.
25. Wang K, Liu J, Yan ZL, Li J, Shi LH, et al. Overexpression of aspartyl-(asparaginyl)-beta-hydroxylase in hepatocellular carcinoma is associated with worse surgical outcome. Hepatology 2010;52:164-73.
26. Lee JH, Lee Y, Lee M, Heo MK, Song JS, et al. A phase I/IIa study of adjuvant immunotherapy with tumour antigen-pulsed dendritic cells in patients with hepatocellular carcinoma. Br J Cancer 2015;113:1666-76.
27. Lee JH, Tak WY, Lee Y, Heo MK, Song JS, et al. Adjuvant immunotherapy with autologous dendritic cells for hepatocellular carcinoma, randomized phase II study. Oncoimmunology 2017;6:e1328335.
28. Zhou Y, Liu F, Li C, Shi G, Xu X, et al. Construction and characterization of adenovirus vectors encoding aspartate-beta-hydroxylase to preliminary application in immunotherapy of hepatocellular carcinoma. J Immunol Res 2018;2018:9832467.
29. Chen C, Ma YH, Zhang YT, Zhang F, Zhou N, et al. Effect of dendritic cell-based immunotherapy on hepatocellular carcinoma: a systematic review and meta-analysis. Cytotherapy 2018;20:975-89.
30. Mo HY, Liao YY, You XM, Cucchetti A, Yuan BH, et al. Timely meta-analysis on the efficacy of adoptive immunotherapy for hepatocellular carcinoma patients after curative therapy. PLoS One 2017;12:e0174222.
31. Ding M, Wang Y, Chi J, Wang T, Tang X, et al. Is adjuvant cellular immunotherapy essential after TACE-predominant minimally-invasive treatment for hepatocellular carcinoma? A systematic meta-analysis of studies including 1774 patients. PLoS One 2016;11:e0168798.
32. Liu Y, Chen X, Han W, Zhang Y. Tisagenlecleucel, an approved anti-CD19 chimeric antigen receptor T-cell therapy for the treatment of leukemia. Drugs Today (Barc) 2017;53:597-608.
33. Gao H, Li K, Tu H, Pan X, Jiang H, Shi B, et al. Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma. Clin Cancer Res 2014;20:6418-28.
34. Jiang Z, Jiang X, Chen S, Lai Y, Wei X, et al. Anti-GPC3-CAR T cells suppress the growth of tumor cells in patient-derived xenografts of hepatocellular carcinoma. Front Immunol 2016;7:690.
35. Wang P, Qin W, Liu T, Jiang D, Cui L, et al. PiggyBac-engineered T cells expressing a glypican-3-specific chimeric antigen receptor show potent activities against hepatocellular carcinoma. Immunobiology 2020;225:151850.
36. Chen C, Li K, Jiang H, Song F, Gao H, et al. Development of T cells carrying two complementary chimeric antigen receptors against glypican-3 and asialoglycoprotein receptor 1 for the treatment of hepatocellular carcinoma. Cancer Immunol Immunother 2017;66:475-89.
37. Guo X, Jiang H, Shi B, Zhou M, Zhang H, et al. Disruption of PD-1 enhanced the anti-tumor activity of chimeric antigen receptor T cells against hepatocellular carcinoma. Front Pharmacol 2018;9:1118.
38. Pan Z, Di S, Shi B, Jiang H, Shi Z, et al. Increased antitumor activities of glypican-3-specific chimeric antigen receptor-modified T cells by coexpression of a soluble PD1-CH3 fusion protein. Cancer Immunol Immunother 2018;67:1621-34.
39. Wu X, Luo H, Shi B, Di S, Sun R, et al. Combined antitumor effects of Sorafenib and GPC3-CAR T cells in mouse models of hepatocellular carcinoma. Mol Ther 2019;27:1483-94.
40. Wang Y, Chen M, Wu Z, Tong C, Dai H, et al. CD133-directed CAR T cells for advanced metastasis malignancies: a phase I trial. Oncoimmunology 2018;7:e1440169.
41. Sun B, Yang D, Dai H, Liu X, Jia R, et al. Eradication of hepatocellular carcinoma by NKG2D-based CAR-T cells. Cancer Immunol Res 2019;7:1813-23.
42. Zhang RY, Wei D, Liu ZK, Yong YL, Wei W, et al. Doxycycline inducible chimeric antigen receptor T cells targeting CD147 for hepatocellular carcinoma therapy. Front Cell Dev Biol 2019;7:233.
43. Yoon JS, Song BG, Lee JH, Lee HY, Kim SW, et al. Adjuvant cytokine-induced killer cell immunotherapy for hepatocellular carcinoma: a propensity score-matched analysis of real-world data. BMC Cancer 2019;19:523.
44. Wang L, Simons DL, Lu X, Tu TY, Solomon S, et al. Connecting blood and intratumoral Treg cell activity in predicting future relapse in breast cancer. Nat Immunol 2019;20:1220-30.
45. Yu R, Yang B, Chi X, Cai L, Liu C, et al. Efficacy of cytokine-induced killer cell infusion as an adjuvant immunotherapy for hepatocellular carcinoma: a systematic review and meta-analysis. Drug Des Devel Ther 2017;11:851-64.
46. Chen CL, Pan QZ, Zhao JJ, Wang Y, Li YQ, et al. PD-L1 expression as a predictive biomarker for cytokine-induced killer cell immunotherapy in patients with hepatocellular carcinoma. Oncoimmunology 2016;5:e1176653.
47. Zhu W, Peng Y, Wang L, Hong Y, Jiang X, et al. Identification of alpha-fetoprotein-specific T-cell receptors for hepatocellular carcinoma immunotherapy. Hepatology 2018;68:574-89.
48. Sun L, Guo H, Jiang R, Lu L, Liu T, et al. Engineered cytotoxic T lymphocytes with AFP-specific TCR gene for adoptive immunotherapy in hepatocellular carcinoma. Tumour Biol 2016;37:799-806.
49. Tan AT, Yang N, Lee Krishnamoorthy T, Oei V, Chua A, et al. Use of expression profiles of HBV-DNA integrated into genomes of hepatocellular carcinoma cells to select T cells for immunotherapy. Gastroenterology 2019;156:1862-76.e9.
50. Qasim W, Brunetto M, Gehring AJ, Xue SA, Schurich A, et al. Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient. J Hepatol 2015;62:486-91.
51. Tian W, Ma J, Shi R, Ren C, He J, et al. gammadelta T cell-mediated individualized immunotherapy for hepatocellular carcinoma considering clinicopathological characteristics and immunosuppressive factors. Oncol Lett 2018;15:5433-42.
52. Kamiya T, Chang YH, Campana D. Expanded and activated natural killer cells for immunotherapy of hepatocellular carcinoma. Cancer Immunol Res 2016;4:574-81.
53. Qian L, Wang N, Tian H, Jin H, Zhao H, et al. Dual Effects of cellular immunotherapy in inhibition of virus replication and prolongation of survival in HCV-positive hepatocellular carcinoma patients. J Immunol Res 2016;2016:6837241.
